491 reports of this reaction
3.4% of all PERAMPANEL reports
#4 most reported adverse reaction
SOMNOLENCE is the #4 most commonly reported adverse reaction for PERAMPANEL, manufactured by Catalyst Pharmaceuticals, Inc.. There are 491 FDA adverse event reports linking PERAMPANEL to SOMNOLENCE. This represents approximately 3.4% of all 14,467 adverse event reports for this drug.
Patients taking PERAMPANEL who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is moderately reported among PERAMPANEL users, representing a notable but not dominant share of adverse events.
In addition to somnolence, the following adverse reactions have been reported for PERAMPANEL:
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 491 FDA reports for PERAMPANEL. This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 3.4% of all adverse event reports for PERAMPANEL, making it a notable side effect.
If you experience somnolence while taking PERAMPANEL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.